Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of pulmonary hypertension.

Literature DB >> 12702599

Treatment of pulmonary hypertension.

Andrew J Peacock.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2003 PMID： 12702599 PMCID： PMC1125759 DOI： 10.1136/bmj.326.7394.835

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

13 in total

1. Bosentan therapy for pulmonary arterial hypertension.

Authors: Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau
Journal: N Engl J Med Date: 2002-03-21 Impact factor: 91.245

2. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Authors: R N Channick; G Simonneau; O Sitbon; I M Robbins; A Frost; V F Tapson; D B Badesch; S Roux; M Rainisio; F Bodin; L J Rubin
Journal: Lancet Date: 2001-10-06 Impact factor: 79.321

3. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors: J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal: N Engl J Med Date: 2001-08-02 Impact factor: 91.245

4. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.

Authors: R D Machado; M W Pauciulo; J R Thomson; K B Lane; N V Morgan; L Wheeler; J A Phillips; J Newman; D Williams; N Galiè; A Manes; K McNeil; M Yacoub; G Mikhail; P Rogers; P Corris; M Humbert; D Donnai; G Martensson; L Tranebjaerg; J E Loyd; R C Trembath; W C Nichols
Journal: Am J Hum Genet Date: 2000-12-12 Impact factor: 11.025

5. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

Authors: V V McLaughlin; D E Genthner; M M Panella; S Rich
Journal: N Engl J Med Date: 1998-01-29 Impact factor: 91.245

6. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.

Authors: Evangelos Michelakis; Wayne Tymchak; Dale Lien; Linda Webster; Kyoko Hashimoto; Stephen Archer
Journal: Circulation Date: 2002-05-21 Impact factor: 29.690

7. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Authors: Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin
Journal: Am J Respir Crit Care Med Date: 2002-03-15 Impact factor: 21.405

8. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension.

Authors: N Nagaya; M Uematsu; H Oya; N Sato; F Sakamaki; S Kyotani; K Ueno; N Nakanishi; M Yamagishi; K Miyatake
Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405

9. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.

Authors: Hossein Ardeschir Ghofrani; Ralph Wiedemann; Frank Rose; Ralph T Schermuly; Horst Olschewski; Norbert Weissmann; Andreas Gunther; Dieter Walmrath; Werner Seeger; Friedrich Grimminger
Journal: Lancet Date: 2002-09-21 Impact factor: 79.321

10. Inhaled iloprost for severe pulmonary hypertension.

Authors: Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245

5 in total

1. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

Authors: Carl Rudolf Blankart; Tom Stargardt; Jonas Schreyögg
Journal: Pharmacoeconomics Date: 2011-01 Impact factor: 4.981

2. Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States.

Authors: Marshaleen Henriques-Forsythe; Srinadh Annangi; Harrison W Farber
Journal: Pulm Circ Date: 2015-09 Impact factor: 3.017